Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: Implications for clinical translation

by McMillin D.W., Delmore J., Negri J., Ooi M., Klippel S., Miduturu C.V., Gray N.S., Richardson P.G., Anderson K.C., Kung A.L., Mitsiades C.S.
Published 2019

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

by Moore, N.F, Azarova, A.M, Bhatnagar, N, Ross, K.N, Drake, L.E, Frumm, S, Liu, Q.S, Christie, A.L, Sanda, T, Chesler, L, Kung, A.L, Gray, N.S, Stegmaier, K, George, R.E
Published 2020